Powder: -20°C for 3 years
In solvent: -80°C for 2 years
PAT-505 is a selective, noncompetitive and orally available inhibitor of autotaxin(IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma).
Description | PAT-505 is a selective, noncompetitive and orally available inhibitor of autotaxin(IC50 of 2 nM in Hep3B cells, 9.7 nM in human blood and 62 nM in mouse plasma). |
Targets&IC50 | Autotaxin:9.7 nM (in human blood ), Autotaxin:2 nM (In Hep3B cells), Autotaxin:62 nM (in mouse plasma) |
In vivo | PAT-505 is a potent, selective, noncompetitive inhibitor that displays significant inhibition of ATX activity in plasma and liver tissue after oral administration.?When dosed therapeutically in a Stelic Mouse Animal Model of nonalcoholic steatohepatitis (NASH), PAT-505 treatment resulted in a small but significant improvement in fibrosis with only minor improvements in hepatocellular ballooning and hepatic inflammation. |
Molecular Weight | 473.92 |
Formula | C23H18ClF2N3O2S |
CAS No. | 1782070-22-7 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 48.33 mg/mL (101.98 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PAT-505 1782070-22-7 Metabolism PDE PAT 505 PAT505 Inhibitor inhibitor inhibit